Peptides for Kidney Stones Prevention: Novel Inhibitors

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide-based therapies are emerging as a novel strategy for kidney stone prevention by inhibiting crystal formation and aggregation. These targeted interventions offer a new approach to reduce recurrence rates and manage nephrolithiasis.

Peptides for Kidney Stone Prevention: A Novel Approach to Oxalate Reduction

Kidney stones, particularly those composed of calcium oxalate, are a prevalent and painful condition affecting millions. The recurrence rate is alarmingly high, with up to 80% of individuals experiencing another stone within 10 years. This reflects a significant gap in current preventative strategies. While traditional advice often focuses on hydration and dietary modifications, emerging research points to peptide-based therapies as a promising new frontier for kidney stone prevention, specifically by targeting oxalate levels.

The Role of Oxalate in Kidney Stone Formation

Approximately 70-80% of all kidney stones are calcium oxalate stones. Even small increases in urinary oxalate significantly elevate the risk of stone development. Currently, no FDA-approved drugs specifically reduce urine oxalate, highlighting a critical unmet need. The gut bacterium Oxalobacter formigenes (Of) is known to induce colonic oxalate secretion, thereby reducing urinary oxalate excretion. However, using Of as a therapeutic agent has proven problematic due to difficulties with recolonization.

Peptide-Based Strategies for Oxalate Reduction

Oxalo Therapeutics has identified that factors derived from Oxalobacter formigenes, including a family of signaling proteins and specific peptides, can significantly stimulate oxalate transport. These peptides have shown promise in reducing urinary oxalate in hyperoxaluric mice by over 32.5%. Importantly, these peptides also stimulated oxalate transport in human organoids, an ex vivo intestinal epithelium model that closely mimics the human gut, underscoring their potential human relevance.

Mechanism of Action:

• Targeting Intestinal Oxalate Excretion: The identified peptides work by enhancing the intestinal excretion of oxalate, effectively removing it from the body before it can contribute to stone formation in the kidneys.
• Addressing Both Dietary and Liver Oxalate: Unlike many current approaches that target either dietary oxalate or liver oxalate, these peptide-based drugs offer a mechanistic advantage by addressing both sources. This means they can extract oxalate from the blood and enhance its intestinal excretion, providing a more comprehensive solution.

Clinical Implications and Future Directions

The development of an oral peptide-based drug to reduce urine and blood oxalate levels holds significant promise for patients suffering from recurrent kidney stones, particularly those with hyperoxaluria. This approach could immediately benefit an estimated 2.7 million patients in the US alone, representing a substantial market for a first-in-class therapy.

Optimizing Peptides for Stability and Efficacy:

Research efforts are focused on:

• Optimizing Lead Peptides: Structural modifications are being explored to enhance the stability of lead peptides, ensuring their effectiveness when administered orally.
• Evaluating Therapeutic Effects: Optimized peptides are rigorously evaluated in animal models of primary hyperoxaluria (PH1) and enteric (secondary) hyperoxaluria to assess their ability to reduce urine and plasma oxalate levels.
• Developing Novel Peptides: Based on modeling of identified crystal structures, novel peptides are being developed to further improve efficacy.
• Enteric-Coated Capsules: The goal is to develop enteric-coated capsules containing the best-performing peptides for oral administration, ensuring targeted delivery and optimal absorption.
• Preclinical Toxicology and Pharmacokinetics: Comprehensive studies are conducted in rats and nonhuman primates to assess the safety and pharmacokinetic profile of these peptide drugs.

Practical Takeaway

If you're prone to kidney stones, especially calcium oxalate stones, discuss with your physician the potential for novel peptide-based therapies as they advance through clinical development. While awaiting these advancements, continue to prioritize adequate hydration and dietary modifications as recommended by your healthcare provider. Staying informed about these innovative treatments could offer a new path to effective prevention.

References

[1] Arvans, D. (2018). Developing a peptide-based oral drug to prevent kidney stones. Grantome. Retrieved from https://grantome.com/grant/NIH/R42-DK120261-01